Viking Therapeutics Inc
VKTX35.720USD
-0.210-0.58%
收盘 10/27, 16:00（美东）报价延迟15分钟
4.02B总市值
亏损市盈率 TTM
关于 Viking Therapeutics Inc 公司
Viking Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发治疗代谢和内分泌疾病的疗法。该公司的临床项目包括 VK2809，这是一种口服小分子选择性甲状腺激素受体 β 激动剂，用于治疗脂质和代谢疾病，目前正在进行 II b 期研究，以评估其治疗活检证实的非酒精性脂肪性肝炎 (NASH) 和纤维化的效果。该公司正在开发 VK0214，这也是一种口服组织和受体亚型选择性 TRb 激动剂，用于治疗 X 连锁肾上腺脑白质营养不良 (X-ALD)，这是一种罕见的 X 连锁遗传性神经系统疾病，其特征是大脑和神经细胞周围的保护屏障被破坏。该公司还在开发 VK2735，这是胰高血糖素样肽 1 (GLP-1) 和葡萄糖依赖性胰岛素促泌多肽 (GIP) 受体的双重激动剂，用于治疗各种代谢紊乱。
Viking Therapeutics Inc简介
公司代码VKTX
公司名称Viking Therapeutics Inc
上市日期Apr 29, 2015
CEODr. Brian W. Lian, Ph.D.
员工数量36
证券类型Ordinary Share
年结日Apr 29
公司地址9920 Pacific Heights Blvd, Suite 350
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92121
电话18587044660
网址https://vikingtherapeutics.com/
公司代码VKTX
上市日期Apr 29, 2015
CEODr. Brian W. Lian, Ph.D.
Viking Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
Mr. J. Matthew Singleton, CPA
Mr. J. Matthew Singleton, CPA
Independent Director
Independent Director
--
--
Dr. Brian W. Lian, Ph.D.
Dr. Brian W. Lian, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.97%
Fidelity Management & Research Company LLC
6.75%
BlackRock Institutional Trust Company, N.A.
3.81%
State Street Investment Management (US)
3.34%
JP Morgan Asset Management
2.22%
其他
74.91%
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.97%
Fidelity Management & Research Company LLC
6.75%
BlackRock Institutional Trust Company, N.A.
3.81%
State Street Investment Management (US)
3.34%
JP Morgan Asset Management
2.22%
其他
74.91%
股东类型
持股股东
占比
Investment Advisor
37.12%
Investment Advisor/Hedge Fund
13.31%
Hedge Fund
8.64%
Research Firm
4.75%
Individual Investor
2.14%
Sovereign Wealth Fund
1.56%
Pension Fund
0.71%
Family Office
0.53%
Bank and Trust
0.53%
其他
30.70%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
889
76.32M
67.87%
-18.54M
2025Q2
873
80.91M
71.95%
-19.10M
2025Q1
881
81.93M
72.95%
-19.61M
2024Q4
837
90.73M
82.19%
-16.87M
2024Q3
781
90.59M
82.61%
-15.25M
2024Q2
701
89.78M
82.34%
-10.20M
2024Q1
634
89.55M
82.55%
-7.02M
2023Q4
464
85.12M
85.96%
-16.14M
2023Q3
442
85.70M
86.63%
-10.01M
2023Q2
426
82.52M
83.46%
-982.32K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
10.14M
9.02%
-3.81K
-0.04%
Jun 30, 2025
Fidelity Management & Research Company LLC
7.63M
6.78%
-2.60M
-25.41%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.31M
3.83%
-564.54K
-11.59%
Jun 30, 2025
State Street Investment Management (US)
3.78M
3.36%
-279.73K
-6.90%
Jun 30, 2025
JP Morgan Asset Management
2.51M
2.24%
-188.76K
-6.99%
Jun 30, 2025
Two Sigma Investments, LP
2.41M
2.14%
+2.35M
+4488.87%
Jun 30, 2025
Fidelity Institutional Asset Management
2.19M
1.95%
+1.17M
+114.64%
Jun 30, 2025
Susquehanna International Group, LLP
2.07M
1.84%
+389.85K
+23.25%
Jun 30, 2025
Lian (Brian)
1.94M
1.73%
+21.44K
+1.12%
Jul 03, 2025
Geode Capital Management, L.L.C.
1.92M
1.71%
-61.08K
-3.08%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月6日 周一
更新时间: 10月6日 周一
机构名称
占比
Roundhill GLP-1 & Weight Loss ETF
2.99%
Amplify Weight Loss Drug & Treatment ETF
1.94%
ALPS Medical Breakthroughs ETF
1.78%
Formidable ETF
1.49%
SPDR S&P Biotech ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.74%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
Tema Heart & Health ETF
0.2%
Inspire Small/Mid Cap ESG ETF
0.18%
Motley Fool Next Index ETF
0.14%
查看更多
Roundhill GLP-1 & Weight Loss ETF
占比2.99%
Amplify Weight Loss Drug & Treatment ETF
占比1.94%
ALPS Medical Breakthroughs ETF
占比1.78%
Formidable ETF
占比1.49%
SPDR S&P Biotech ETF
占比1.03%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.74%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.63%
Tema Heart & Health ETF
占比0.2%
Inspire Small/Mid Cap ESG ETF
占比0.18%
Motley Fool Next Index ETF
占比0.14%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
